E

Eisai

China - Liaoning
Biotechnology5 H-1B visas (FY2023)
WebsiteLinkedInCareers Page

Focus: Small Molecules

Error: Unreachable/Blocked

OncologyNeurologyImmunologyGastroenterologyMetabolic Diseases
Open Jobs
0

Products & Portfolio (10)

5 discontinued products not shown

ACIPHEX
rabeprazole sodium
LOE Approaching
Oral · Tablet, Delayed Release
(substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H 2 -receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H, KATPase at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro , rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds. It inhibits acid transport in porcine gastric vesicles with a half-life of 90 seconds.
daytimenighttime heartburnother symptoms associated with GERD in adults for up to 4 weeks+3 more
2002
30
ARICEPT
donepezil hydrochloride
LOE Approaching
ORAL · TABLET
Alzheimer's disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.
dementia of the Alzheimer's typeAlzheimer's disease
1996
30
ARICEPT
donepezil hydrochloride
LOE Approaching
ORAL · TABLET
Alzheimer's disease attribute some of them to a deficiency of cholinergic neurotransmission. Donepezil hydrochloride is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. There is no evidence that donepezil alters the course of the underlying dementing process.
dementia of the Alzheimer's typeAlzheimer's disease
2010
25
BANZEL
rufinamide
LOE Approaching
ORAL · SUSPENSION
mechanism(s) by which rufinamide exerts its antiepileptic effect is unknown. The results of in vitro studies suggest that the principal mechanism of action of rufinamide is modulation of the activity of sodium channels and, in particular, prolongation of the inactive state of the channel. Rufinamide (≥ 1 μM) significantly slowed sodium channel recovery from inactivation after a prolonged prepulse in cultured cortical neurons, and limited sustained repetitive firing of sodium-dependent action potentials (EC 50 of 3.8 μM).
2011
30
DAYVIGO
lemborexant
Peak
ORAL · TABLET
Orexin Receptor Antagonists
characterized by difficulties with sleep onset and/or sleep maintenanceinsomnia
2019
0
HALAVEN
eribulin mesylate
LOE Approaching
INTRAVENOUS · SOLUTION
2010
15
LENVIMA
lenvatinib
Peak
ORAL · CAPSULE
Receptor Tyrosine Kinase Inhibitors
2015
0
LEQEMBI
lecanemab
Peak
mAbINJECTION · INJECTABLE
Amyloid Beta-directed Antibody Interactions
2023
30
LEQEMBI IQLIK
lecanemab-irmb
Launch
mAbSUBCUTANEOUS · INJECTABLE
Amyloid Beta-directed Antibody Interactions
2025
30
ONTAK
denileukin diftitox
LOE Approaching
VIAL
1999
30

Pipeline & Clinical Trials

No treatment
Epilepsy
N/A
Clinical Trials (1)
NCT02736162Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy
N/A
N/A
Clinical Trials (1)
NCT01023867Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
N/A
A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Pat
Alzheimer's Disease
N/A
Clinical Trials (1)
NCT02262975A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)
N/A
N/A
Clinical Trials (1)
NCT01321567Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
N/A
Lorcaserin
Obesity
N/A
Clinical Trials (1)
NCT02388568Lifestyle Modification and Lorcaserin for Weight Loss Maintenance
N/A
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008
Metastatic Breast Cancer
N/A
Post-Marketing Surveillance of Lenvima in Korean Patients
Differentiated Thyroid Carcinoma (DTC)
N/A
Clinical Trials (1)
NCT02764554Post-Marketing Surveillance of Lenvima in Korean Patients
N/A
Surveillance of Humira Injection in Korean Patients
Rheumatoid Arthritis
N/A
No Intervention
Gastric Ulcer
N/A
Clinical Trials (1)
NCT02423187Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin
N/A
Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Thera
Arthritis, Rheumatoid
N/A
Clinical Trials (1)
NCT03264703Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World
N/A
3 Screen Electronic Alert
Deep Vein Thrombosis
N/A
Clinical Trials (1)
NCT005500823 Screen Electronic Alert
N/A
Eslicarbazepine Acetate tablets
Partial Onset Seizures
N/A
Clinical Trials (1)
NCT01830400A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)
N/A
Lorcaserin
Obesity
N/A
Clinical Trials (1)
NCT03552107Lorcaserin: Real World Experience in an Insurance-Based Weight Management Clinic
N/A
N/A
Clinical Trials (1)
NCT05366036A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
N/A
Lenvatinib
Thyroid Cancer
N/A
Clinical Trials (1)
NCT03533361Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil
N/A
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT02790320Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer
N/A
Extended Treatment in Metastatic Breast Cancer With Eribulin
Breast Cancer
N/A
Clinical Trials (1)
NCT02769364Extended Treatment in Metastatic Breast Cancer With Eribulin
N/A
N/A
Clinical Trials (1)
NCT04763408A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
N/A
N/A
Clinical Trials (1)
NCT05228158A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
N/A
N/A
Clinical Trials (1)
NCT04252846A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy
N/A
Dalteparin sodium
Venous Thromboembolism
N/A
Clinical Trials (1)
NCT01050153The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma
N/A
N/A
Clinical Trials (1)
NCT05208268A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer
N/A
Eribulin Mesylate
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT03245112Halaven Patient Registry (Metastatic Breast Cancer, MBC)
N/A
Halaven Post-Marketing Surveillance (PMS)
Breast Cancer
N/A
Clinical Trials (1)
NCT02441764Halaven Post-Marketing Surveillance (PMS)
N/A
N/A
Clinical Trials (1)
NCT02430714Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
N/A
Usual care setting
Mild Cognitive Impairment
N/A
Clinical Trials (1)
NCT03448445A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
N/A
Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Res
Inflammatory Bowel Disease
N/A
Clinical Trials (1)
NCT03264690Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients
N/A
donepezil hydrochloride
Alzheimer's Disease
N/A
Clinical Trials (1)
NCT01129596Post-marketing Surveillance of Long-term Administration of Donepezil Hydrochloride -Investigation of the Clinical Condition and Safety in Patients With Alzheimer's Disease-
N/A
Zonisamide tablets
Partial Onset Seizures
N/A
Clinical Trials (1)
NCT01830868A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)
N/A
N/A
Clinical Trials (1)
NCT04257604A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures
N/A
N/A
Clinical Trials (1)
NCT01289483Fospropofol for Sedation During Elective Awake Intubation
N/A
Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
Breast Cancer
N/A
Clinical Trials (1)
NCT02443428Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry
N/A
Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflamma
Lumbar Disc Degenerative Disease
N/A
Clinical Trials (1)
NCT01299077Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China
N/A
N/A
Clinical Trials (1)
NCT06744673A Study to Assess the Pregnancy Outcome in Women Exposed to Dayvigo® During Pregnancy Compared to an Unexposed Control Population
N/A
MRS Spectroscopy
Glioblastoma Multiforme
N/A
Clinical Trials (1)
NCT00645385Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme.
N/A
N/A
Clinical Trials (1)
NCT03027245Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy
N/A
ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
Focal Epilepsy
N/A
Clinical Trials (1)
NCT03082222ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions
N/A
Non-interventional
Arthritis, Rheumatoid
N/A
Clinical Trials (1)
NCT06246123A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants
N/A
Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for
Breast Cancer
N/A
Clinical Trials (1)
NCT02863146Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer
N/A
Eribulin Mesylate
Breast Cancer
N/A
Clinical Trials (1)
NCT01142661Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
N/A
N/A
Clinical Trials (1)
NCT03020797A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)
N/A
N/A
Clinical Trials (1)
NCT03663114A Post-marketing Observational Study on Risk Factors for Hepatic Encephalopathy in Participants With Unresectable Hepatocellular Carcinoma
N/A
Lecanemab treatment group
Alzheimer's Disease
N/A
Clinical Trials (1)
NCT06871839The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease
N/A
Perampanel
Epilepsy
N/A
Clinical Trials (1)
NCT02033902A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years
N/A
N/A
Clinical Trials (1)
NCT03778424An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303
N/A
N/A
Clinical Trials (1)
NCT01264822Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
N/A
N/A
Clinical Trials (1)
NCT02307578An Extended Access Program (EAP) for Perampanel
N/A
No Intervention
Biliary Tract Cancer
N/A
Clinical Trials (1)
NCT06793709A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
N/A
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of th
Cervical Dystonia
N/A
Clinical Trials (1)
NCT02175693Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
N/A
N/A
Clinical Trials (1)
NCT05137847A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)
N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts
Portfolio: 15 approved products, 148 clinical trials
Top TAs: Oncology, Neurology, Gastroenterology
H-1B (2023): 5 approvals
Portfolio Health
Launch1 (7%)
Peak3 (20%)
LOE Approaching11 (73%)
15 total products
Therapeutic Area Focus
Oncology
1 marketed325 pipeline
Neurology
6 marketed163 pipeline
Gastroenterology
1 marketed24 pipeline
Immunology
19 pipeline
Cardiovascular
7 pipeline
Respiratory
7 pipeline
Marketed
Pipeline

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
5
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub